HCRT and pancreatic neoplasm: To determine the biological functions of orexin-A in pancreatic cancer, we activated or inactivated the stimulation of OX1Rby incubation with different concentrations (10−5, 10−6, 10−7, and 10−8 M) of orexin-A with or without treatment of SB408124 (50 nM), an OX1 receptor antagonist to prevent the orexin-A effect on cell proliferation in PANC1 cells (data not shown).